Japanese Journal of Clinical Chemistry
Online ISSN : 2187-4077
Print ISSN : 0370-5633
ISSN-L : 0370-5633
Volume 35, Issue 2
Displaying 1-6 of 6 articles from this issue
  • Kazuhiko Matsuno, Takanori Yasushi
    2006 Volume 35 Issue 2 Pages 105-112
    Published: April 28, 2006
    Released on J-STAGE: November 27, 2012
    JOURNAL FREE ACCESS
    Download PDF (1022K)
  • Akitada Ichinose
    2006 Volume 35 Issue 2 Pages 113-118
    Published: April 28, 2006
    Released on J-STAGE: November 27, 2012
    JOURNAL FREE ACCESS
    Download PDF (792K)
  • especially antiphospholipid syndrome
    Masahiro Ieko, Toru Nakabayashi, Takashi Tarumi, Sumiyoshi Naito, Mika ...
    2006 Volume 35 Issue 2 Pages 119-128
    Published: April 28, 2006
    Released on J-STAGE: November 27, 2012
    JOURNAL FREE ACCESS
    Download PDF (5557K)
  • Tetsuhito Kojima
    2006 Volume 35 Issue 2 Pages 129-135
    Published: April 28, 2006
    Released on J-STAGE: November 27, 2012
    JOURNAL FREE ACCESS
    Download PDF (2664K)
  • Masahiro Tohkin
    2006 Volume 35 Issue 2 Pages 136-143
    Published: April 28, 2006
    Released on J-STAGE: November 27, 2012
    JOURNAL FREE ACCESS
    Bile acids, which were biosynthesized from cholesterol in the liver, had been considered to prompt the lipids absorption in the intestine as a detergent. In 1999, independent three research groups reported that bile acids functioned as endogenous and physiologically relevant ligands for the orphan nuclear receptor, farnesoid X receptor (FXR). This breakthrough discovery has leaded the research of bile acids homeostasis. These researches clarified that bile acids-activated FXR regulated not only CYP7A1 expression, the rate-limiting enzyme of bile acids biosynthesis, but also bile acids transporters, which regulated the bile acids enterohepatic circulations. Recently, it was reported that the activated FXR improved the hyperglycemia and hyperlipemia in the diabetic mice. These results suggested that FXR regulated the glucose metabolism in addition to the bile acids metabolism.
    Download PDF (2689K)
  • Yasunori Nagamine, Shigemi Hohogaya, Kazuhisa Itoh, Susumu Osawa, Yuzo ...
    2006 Volume 35 Issue 2 Pages 144-153
    Published: April 28, 2006
    Released on J-STAGE: November 27, 2012
    JOURNAL FREE ACCESS
    The allowable limits of error against 36 clinical biochemical analytes to establish the analytical quality specifications were investigated. These quality specifications were based on the analyses of physiological and biological variations with normal data in 9 studies published after 1990. These studies were performed against Japanese healthy volunteers and biochemical data were collected more than 10 weeks.
    Desirable quality specifications for imprecision and bias were estimated using the following formulae, which was proposed by Fraser & Harris: Imprecision one-half of the average within-subject biological variation: 1/2CVI. Bias one-quarter of the group (within-plus between-subject) biological variation: 1/4 (CVG2+CVI) 1/2.
    The results of quality specification were obtained very similar to those of Fraser's (Fraser CG, 1992) and Ricós' (Ricós C, 1999). These quality specifications are met with international requirement, and it will be possible to accept in laboratory medicine.
    The quality specifications for imprecision can be used as the criteria of internal quality control, and those for bias can be also used as criteria of measurement values of control materials and the external quality assessment schemes.
    Download PDF (1403K)
feedback
Top